Acquired Angioedema with C1 Inhibitor Deficiency: A Patient Guide

Scope Statement: This guide is for people with clinician-confirmed or suspected AAE-C1-INH. Swelling has other causes, and proper evaluation is required. The evidence cited in this guide is derived from published medical literature, and some treatments are extrapolated from Hereditary Angioedema (HAE) guidance.

Acquired Angioedema with C1 Inhibitor Deficiency (AAE-C1-INH) is a rare condition characterized by episodes of deep, temporary swelling in the skin or the lining of internal organs. Unlike common allergic reactions, which are triggered by histamine, these attacks are driven by an overproduction of a peptide called bradykinin ^[1]. Because the underlying biology is different, the swelling does not typically cause hives or itching, and it does not respond to standard allergy treatments like antihistamines, steroids, or epinephrine ^[2]. For many patients, the diagnosis comes later in life after a “diagnostic odyssey” of trying to treat these episodes as if they were simple allergies ^[3].

The condition is called “acquired” because it is not inherited through family genes but instead develops as a result of changes within the body’s immune or blood-producing systems. Specifically, it occurs when the body begins to consume or disable its supply of C1 Inhibitor, a protein that normally acts as a “brake” to keep bradykinin levels in check ^[4]. This deficiency is often a secondary signal of an underlying condition, most commonly a B-cell lymphoproliferative disorder or a plasma cell issue like MGUS ^[5]. Because the swelling can sometimes precede a formal diagnosis of these underlying conditions by several years, ongoing and individualized screening by a hematologist is a vital part of long-term care ^[6].

Managing AAE-C1-INH requires a dual approach: stopping active attacks and addressing the root cause. While swelling in the hands, feet, or abdomen can be painful and disruptive, swelling in the throat or airway is a life-threatening emergency that requires immediate medical attention and specific “pathway-targeted” therapies ^[7]. Beyond managing individual episodes, the most effective way to control the frequency of attacks is often to treat the underlying blood or immune disorder ^[8]. By focusing on the root cause—frequently through targeted immunotherapies—many patients are able to achieve clinical remission, where the swelling attacks significantly decrease or disappear entirely ^[5].

While a diagnosis of a rare disease later in life can feel overwhelming, it also provides the roadmap needed to reclaim control. Moving away from ineffective allergy treatments and toward specialized care allows for a targeted management plan that addresses both the immediate symptoms and your overall long-term health. With a dedicated care team that includes both immunologists and hematologists, most patients can navigate the complexities of this condition and live full, active lives ^[9].